Our Tests

Lymphoma Panel

« Back to test list


Changes in chromosome structure and number in lymphoma cells can provide important prognostic and therapeutic information. Based on the differential diagnosis and results of other laboratory investigations, a relevant selection of probes from this panel will be used. The panel covers the most relevant abnormalities in lymphoma: ATM deletion, 13q deletion, TP53 deletion, MALT1 rearrangements and IGH rearrangements. It can confirm the presence of, for example, IGH/CCND1 fusion in Mantle cell lymphoma, IGH/MYC in Burkitt lymphoma, and IGH/BCL2 in follicular lymphoma.

Clinical Utility

The laboratory report defines the changes in the patient’s malignant cells and relates these changes to the current management recommendations.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes to detect the abnormalities noted above.

Test Ordering

This test is usually requested by a haematologist or oncologist.

0.5 mL bone marrow in transport media or 10 mL blood in lithium heparin if clinically appropriate.

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We also recommend that the patient or another adult check the labelling of request forms and sample tubes.



Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Turnaround Time

2 working days.

For Doctors